The original success of Sildenafil undeniably reshaped the medication landscape, but placing funds in companies strongly reliant on off-patent versions presents a complex picture. Despite early returns were substantial, the expiration of patents and the emergence of less expensive alternatives have diminished sales. Consequently, a thorough assessm